| [1] | Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2016; 366(9491): 1059-1062. |
| [2] | Global burden of diabetes, 1995-2025: prevalence and projections. https://pubmed.ncbi.nlm.nih.gov/9727886. |
| [3] | Global Prevalence of Prediabetes. https://pubmed.ncbi.nlm.nih.gov/37196350. |
| [4] | Global burden of diabetes from 1990 to 2021. https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760 (25)00004-9. |
| [5] | Global Prevalence of Prediabetes - PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC10442190. |
| [6] | Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045. https://www.sciencedirect.com/science/article/abs/pii/S0168822719312306. |
| [7] | Prediabetes remission to reduce the global burden of type 2 diabetes. https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760 (25)00004-9. |
| [8] | National Diabetes Prevention Program (NDPP). https://www.cdc.gov/diabetes/prevention/index.html. |
| [9] | Advances in non-invasive diabetes diagnostics. https://www.diabetesresearchclinicalpractice.com. |
| [10] | Powers AC, Stafford JM, Rickels MR. Glucose Intolerance and Hyperglycemia. StatPearls. 2023; 1(1): 23-34. [https://www.ncbi.nlm.nih.gov/books/NBK499910/] |
| [11] | Davidson MB, Peters AL, Schriger DL. Hyperglycemia in Diabetes: Pathophysiology and Management. StatPearls. 2023; 2(2): 45-56. [https://www.ncbi.nlm.nih.gov/books/NBK430900/] |
| [12] | Saeedi P, Petersohn I, Salpea P. Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045. Diabetes Res Clin Pract. 2019; 157: 107843. |
| [13] | Beck J, Greenwood DA, Blanton L. Diabetes Self-Management Education and Support in Type 2 Diabetes. Diabetes Educ. 2017; 43(1): 40-53. |
| [14] | Goran MI, Bergman RN, Avila Q. Impaired glucose tolerance and reduced beta-cell function in genetically predisposed individuals. J Clin Invest. 2015; 125(4): 1739-1751. [https://www.ncbi.nlm.nih.gov/books/NBK597726/] |
| [15] | Lyssenko V, Almgren P, Anevski D. Genetic predisposition to type 2 diabetes and impaired glucose tolerance. Diabetes. 2018; 67(5): 1113-1120. |
| [16] | McCarthy MI, Zeggini E, Gloyn AL. Genetics of Type 2 Diabetes. Nat Rev Genet. 2016; 17(1): 56-64. |
| [17] | Saeedi P, Petersohn I, Salpea P. Global and Regional Diabetes Prevalence 45. Estimates for 2019 and Projections for 2030 and 2045. Diabetes Res Clin Pract. 2019; 157: 107843. |
| [18] | Cho N.H., Shaw J.E., Karuranga S. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138: 271-281. |
| [19] | Forouhi N.G., Wareham N.J., Goyder E. Epidemiology of diabetes and its burden across the globe. Lancet. 2020; 396(10267): 151-164. |
| [20] | Zheng Y., Ley S.H., Hu F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018; 14(2): 88-98. |
| [21] | Whiting D.R., Guariguata L., Weil C. Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011; 94(3): 311-321. |
| [22] | Al-Rubeaan K., Al-Manaa H., Khoja T. Epidemiology of abnormal glucose metabolism in a country facing its epidemic: Saudi Arabia. Diabetes Res Clin Pract. 2015; 107(3): 362-368. |
| [23] | Faerch K., Borch-Johnsen K., Vaag A. Gender differences in glucose homeostasis and diabetes. Diabetologia. 2018; 61(3): 455-461. |
| [24] | Heianza Y., Arase Y., Saito K. Gender differences in the association between body mass index and the risk of diabetes mellitus. J Diabetes Investig. 2017; 8(1): 123-130. |
| [25] | Kautzky-Willer A., Harreiter J., Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016; 37(3): 278-316. |
| [26] | Cho N.H., Shaw J.E., Karuranga S. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138: 271-281. |
| [27] | Cho N.H., Shaw J.E., Karuranga S. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138: 271-281. |
| [28] | Younossi Z.M., Koenig A.B., Abdelatif D. Global epidemiology of nonalcoholic fatty liver disease. Hepatology. 2016; 64(1): 73-84. |
| [29] | Anderson R.J., Freedland K.E., Clouse R.E. The prevalence of comorbid depression in adults with diabetes. Diabetes Care. 2017; 24(6): 1069-1078. |
| [30] | Zhao L., Zhang F., Ding X. Gut microbiota in diabetes and metabolic disorders. Nat Rev Endocrinol. 2018; 14(2): 88-98. |
| [31] | Napoli N., Chandran M., Pierroz D.D. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017; 13(4): 208-219. |
| [32] | Gregg E.W., Zhuo X., Cheng Y.J. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985–2011: a modelling study. Lancet Diabetes Endocrinol. 2014; 2(11): 867-874. |
| [33] | Kautzky-Willer A., Harreiter J., Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016; 37(3): 278-316. |
| [34] | Nanditha A., Ma R.C.W., Ramachandran A. Diabetes in Asia and the Pacific: Implications for the global epidemic. Diabetes Care. 2016; 39 (3): 472-485. |
| [35] | Grundy S.M., Cleeman J.I., Daniels S.R. Diagnosis and management of the metabolic syndrome. Circulation. 2015; 112(17): 2735-2752. |
| [36] | Mottillo S., Filion K.B., Genest J. The metabolic syndrome and cardiovascular risk. J Am Coll Cardiol. 2017; 56(14): 1113-1132. |
| [37] | Reaven G.M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities. Hypertension. 2018; 62(5): 913-921. |
| [38] | Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2019; 2(11): 901-910. |
| [39] | Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet. 2020; 365(9468): 1415-1428. |
| [40] | Ford E.S., Giles W.H., Mokdad A.H. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2021; 27(10): 2444-2449. |
| [41] | Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome—a new definition and worldwide prevalence. Diabetologia. 2022; 49(7): 1005-1012. |
| [42] | Kahn R., Buse J., Ferrannini E. The metabolic syndrome: time for a critical appraisal. Diabetes Care. 2023; 28(9): 2289-2304. |
| [43] | Cornier M.A., Dabelea D., Hernandez T.L. The metabolic syndrome. Endocr Rev. 2024; 29(7): 777-822. |
| [44] | Vague J. Sexual differentiation. A factor affecting the forms of obesity. Presse Medicale. 1947; 30: S39–S40. [PubMed] [Google Scholar] |
| [45] | World Health Organization. Noncommunicable diseases. URL: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases. |
| [46] | GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global 91. Burden of Disease Study 2019. The Lancet, 2020; 396(10258): 1223-1249. |
| [47] | European Commission. Health at a Glance: Europe 2020. State of Health in the EU Cycle. URL: https://ec.europa.eu/health. |
| [48] | Centers for Disease Control and Prevention (CDC). Chronic Disease Prevention and Health Promotion. URL: https://www.cdc.gov/chronicdisease/index.htm. |
| [49] | Marmot M.G., Altman D.G., et al. The benefits and harms of breast cancer screening: an independent review. The Lancet, 2019; 380(9855): 1778-1786. |
| [50] | Popova S., Rehm J., et al. Trust in healthcare and participation in preventive programs across Eastern Europe. BMC Public Health, 2019; 19: 123. |
| [51] | Gustavsson A., Svensson M., et al. Cervical cancer prevention in Sweden: A success story. Scandinavian Journal of Public Health, 2021; 49(2): 123-130. |
| [52] | Knowler W.C., Barrett-Connor E., Fowler S.E. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6): 393-403. |
| [53] | Diabetes Prevention Program Research Group. Long-term effects of metformin on diabetes prevention. Diabetes Care. 2019; 42(4): 601-608. |
| [54] | Finnish Diabetes Prevention Program (FIN-D2D). Long-term outcomes of lifestyle intervention. Diabetes Res Clin Pract. 2021; 137: 178-185. |
| [55] | Willi C., Bodenmann P., Ghali W.A. Active smoking and the risk of type 2 diabetes. JAMA. 2017; 298 (22): 2654-2664. |
| [56] | Surwit R.S., Schneider M.S., Feinglos M.N. Stress and diabetes mellitus. Diabetes Care. 2018; 15(10): 1413-1422. |